Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 82Colorectal Cancer Treatments and StudiesDrug Transport and Resistance MechanismsCancer Cells and Metastasis

The DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index; 263 of the 340 sources its claims cite were checked for support.

Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer

Open access
Haynes, Jennifer, Manogaran, Prasath·2025·International Journal of Molecular Sciences

Abstract

Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide, with a significant impact on public health. Current treatment options include surgery, chemotherapy, radiotherapy, molecular-targeted therapy, and immunotherapy. Despite advancements in these therapeutic modalities, resistance remains a significant challenge, often leading to treatment failure, poor progression-free survival, and cancer recurrence. Mechanisms of resistance in CRC are multifaceted, involving genetic mutations, epigenetic alterations, tumor heterogeneity, and the tumor microenvironment. Understanding these mechanisms at the molecular level is crucial for identifying novel therapeutic targets and developing strategies to overcome resistance. This review provides an overview of the diverse mechanisms driving drug resistance in sporadic CRC and discusses strategies currently under investigation to counteract this resistance. Several promising strategies are being explored, including targeting drug transport, key signaling pathways, DNA damage response, cell death pathways, epigenetic modifications, cancer stem cells, and the tumor microenvironment. The integration of emerging therapeutic approaches that target resistance mechanisms aims to enhance the efficacy of current CRC treatments and improve patient outcomes.

Overview

CoChat Summary

TL;DR

This review summarizes the diverse mechanisms driving drug resistance in sporadic colorectal cancer (CRC)—including drug transport/metabolism, signaling pathway alterations, DNA damage response and cell death defects, epigenetic changes, tumor heterogeneity/CSCs/DTPs, and the tumor microenvironment—and discusses therapeutic strategies under investigation to overcome it. It concludes that combination approaches targeting multiple resistance mechanisms, guided by molecular profiling, hold the most promise.

Key findings

  • Drug resistance in CRC is multifactorial and can be intrinsic or acquired; recurrence occurs in 30–40% of patients who complete treatment, mostly within the first 2–3 years, and resistance has been reported to develop in nearly all CRC patients. Mechanisms include ABC transporter–mediated efflux (PGP/MDR1, BCRP, MRP1/2), altered drug metabolism (GSTs, UGTs, CYPs), secondary mutations/alternative pathway activation (EGFR, RAS/BRAF, PI3K/AKT/mTOR, HER2/MET), enhanced DNA damage response, defective apoptosis/autophagy, epigenetic alterations, CSCs, EMT, DTPs, and the TME.
  • Key molecular features: APC mutated in ~80% of CRCs, KRAS ~40%, BRAF 10–15%, TP53 50–60%, SMAD4 ~15%, PIK3CA ~20%; CIN accounts for ~85% of sporadic CRCs, MSI ~15%, CIMP ~20%. Consensus molecular subtypes: 87% of samples assigned to CMS1–4 (CMS1 14%, CMS2 37%, CMS3 13%, CMS4 23%), with 13% mixed features.
  • Strategies under investigation include targeting ABC transporters (e.g., miRNA mimics miR-133b, miR-142-3p, miR-297, miR-522; nanomedicine), EGFR and alternative pathways (Sym004, anti-HER2/anti-MET, KRAS-G12C inhibitors sotorasib/adagrasib, BRAF+EGFR+MEK combinations), DDR (PARP, ATM, WEE1 inhibitors), cell death pathways (BH3 mimetics, IAP antagonist TL32711, chloroquine/hydroxychloroquine, ferroptosis inducers RSL3/erastin), epigenetic therapies (DNMT, HDAC, EZH2, KDM1A/KDM4 inhibitors; ncRNA modulation), CSCs (LGR5 antibody–drug conjugates, MCLA-158, BiTEs, oncolytic viruses, Wnt/Notch/Hh inhibition, differentiation therapy), and the TME (anti-angiogenic agents, HIF inhibitors, hypoxia-activated prodrug evofosfamide, ECM/LOX targeting, CAF targeting, ICIs, CAR-T cells).
  • The review concludes that CRC heterogeneity and multiple resistance mechanisms make it unlikely that one therapy can eliminate all CRC cells; combination therapies and precision medicine guided by genomic, epigenomic, and molecular profiling are emphasized.

Methods

  • Design: narrative review providing an overview of drug resistance mechanisms in sporadic CRC and strategies under investigation to counteract resistance.
  • Data: published literature, with references cited throughout; no primary patient data or experimental study is reported.
  • Main analysis: narrative synthesis of mechanisms and therapeutic approaches; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.

Limitations

  • Stated: the paper does not include an explicit limitations section for the review itself.
  • Evident: as a narrative review, it lacks a described systematic search strategy, inclusion/exclusion criteria, and quantitative synthesis, so selection and interpretation of evidence may be subject to bias.
  • Evident: the scope is sporadic CRC, and many discussed strategies are preclinical or still under investigation, with clinical utility and biomarker-based patient selection not yet established.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms26051988

Cites

244 of 244 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Therapeutic approaches for colorectal cancer (CRC). The standard therapies for CRC are surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Combinations of standard therapies are often used to treat CRC. Illustration created in https://www.biorender.com/, accessed on 11 February 2025.
Figure 1 Therapeutic approaches for colorectal cancer (CRC). The standard therapies for CRC are surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. Combinations of standard therapies are often used to treat CRC. Illustration created in https://www.biorender.com/, accessed on 11 February 2025.CC BY · PubMed Central
Figure 2 Molecular targets of current anti-CRC drugs. The drugs indicated are FDA-approved for CRC treatment. Chemotherapy drugs are shown in red outline boxes, targeted therapy drugs are shown in blue outline boxes, and immunotherapy agents are shown in green outline boxes. Anti-VEGF/VEGFR therapies also target endothelial cells, and anti-CTLA-4 therapies also target dendritic cells. Illustration created in https://www.biorender.com/.
Figure 2 Molecular targets of current anti-CRC drugs. The drugs indicated are FDA-approved for CRC treatment. Chemotherapy drugs are shown in red outline boxes, targeted therapy drugs are shown in blue outline boxes, and immunotherapy agents are shown in green outline boxes. Anti-VEGF/VEGFR therapies also target endothelial cells, and anti-CTLA-4 therapies also target dendritic cells. Illustration created in https://www.biorender.com/.CC BY · PubMed Central
Figure 3 Mechanisms of drug resistance in CRC. Various molecular and cellular mechanisms contribute to drug resistance in sporadic CRC. ABC, ATP-binding cassette; CSCs, cancer stem cells; DTPs, drug-tolerant persisters. Illustration created in https://www.biorender.com/.
Figure 3 Mechanisms of drug resistance in CRC. Various molecular and cellular mechanisms contribute to drug resistance in sporadic CRC. ABC, ATP-binding cassette; CSCs, cancer stem cells; DTPs, drug-tolerant persisters. Illustration created in https://www.biorender.com/.CC BY · PubMed Central
Figure 4 EGFR signaling pathways. Upon binding of ligands (e.g., EGF), EGFR forms homodimers and initiates intracellular signaling to two downstream pathways, MAPK and PI3K. These signaling pathways lead to transcriptional activation and expression of genes involved in cell growth, proliferation, and signaling. Ligand-bound EGFR can also form heterodimers with other EGFR family receptors such as HER2 or HER3. Proteins in red font are often constitutively activated due to mutation in CRC. TF, transcription factor. Illustration created in https://www.biorender.com/.
Figure 4 EGFR signaling pathways. Upon binding of ligands (e.g., EGF), EGFR forms homodimers and initiates intracellular signaling to two downstream pathways, MAPK and PI3K. These signaling pathways lead to transcriptional activation and expression of genes involved in cell growth, proliferation, and signaling. Ligand-bound EGFR can also form heterodimers with other EGFR family receptors such as HER2 or HER3. Proteins in red font are often constitutively activated due to mutation in CRC. TF, transcription factor. Illustration created in https://www.biorender.com/.CC BY · PubMed Central
Figure 5 Strategies to overcome drug resistance in CRC. Several promising strategies are being explored to overcome drug resistance in sporadic CRC. CDK, cyclin-dependent kinase; CSCs, cancer stem cells; DDR, DNA damage response; DNMT, DNA methyltransferase; ECM, extracellular matrix; HDAC, histone deacetylase; HDM, histone demethylase; HMT, histone methyltransferase; TME, tumor microenvironment. Illustration created in https://www.biorender.com/.
Figure 5 Strategies to overcome drug resistance in CRC. Several promising strategies are being explored to overcome drug resistance in sporadic CRC. CDK, cyclin-dependent kinase; CSCs, cancer stem cells; DDR, DNA damage response; DNMT, DNA methyltransferase; ECM, extracellular matrix; HDAC, histone deacetylase; HDM, histone demethylase; HMT, histone methyltransferase; TME, tumor microenvironment. Illustration created in https://www.biorender.com/.CC BY · PubMed Central

Verification

Claims the paper makes

219 Valid · 5 Not valid · 40 Not checked · 59 Own results and interpretations

165 more claims · 118 with their cited sources checked

Create a free account to see all 323 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 130
  • Probably not a substantial claim. 39

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

1 of 1

Citations

Cites

1 retracted

Show all 249 references

Cited by

See all 82

Metadata

Authors
Haynes, J., & Manogaran, P.
Affiliations
Marshall University (US)
Corresponding author
Haynes, Jennifer
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2025-02-25
Volume
26
Issue
5
Pages
1988
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4407920293
Cited by
82
References
249
Citations by year
2026: 57 · 2025: 24
FWCI
9.46
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
colorectal cancer, drug resistance, resistance mechanisms, epigenetic modifications, tumor heterogeneity, tumor microenvironment, drug transporters, DNA damage response, cell death pathways, cancer stem cells, signaling pathways, therapeutic target
MeSH terms
Animals, Antineoplastic Agents, Humans, Neoplastic Stem Cells, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epigenesis, Genetic, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/ijms26051988
The paper
Haynes, J., & Manogaran, P. (2025). Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26051988

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.